CHU-UCL Namur

Namur 5000

4 studies enrolling now · 6 studies all time

What they study most

Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Cancer, Hodgkin Lymphoma, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Ovarian Cancer

Studies at this site

• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — Recruiting now
• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• Brentuximab Vedotin in Early Stage Hodgkin Lymphoma — Recruiting now
• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) — Recruiting now
• Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer — Stopped early
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling